Vasopressin 40 Units/ 100 Ml & 60 Units/ 100 Ml Cipla 40 & 60 units Solution for injection
PDF Leaflet Revision Date: 08 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated to increase blood pressure in adults with vasodilatory shock.
Dosage (summary)
Starting dose: 0.03 units/min for post-cardiotomy shock; 0.01 units/min for septic shock, titrate as needed.
Onset of Action / Duration
Onset: 15 mins, Duration: 20 mins after stopping infusion.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Increased clearance in pregnancy; may require dose adjustment. Unknown effects during breastfeeding.
Key Drug Interactions
- Catecholamines
- Indomethacin
- Ganglionic Blocking Medicines
- Medicines causing SIADH
- Medicines causing Diabetes Insipidus
Contraindications
- Known allergy to vasopressin or excipients
Common side effects
- Reversible diabetes insipidus
- Hyponatremia
- Right heart failure
- Atrial fibrillation
Counselling Points
- Monitor blood pressure regularly.
- Report any signs of ischemia.
- Stay hydrated and monitor fluid intake.
Serious warnings
- Worsening cardiac function
- Risk of ischemic events
- Monitor for diabetes insipidus
Important Disclaimer
The Vasopressin 40 Units/ 100 Ml & 60 Units/ 100 Ml Cipla 40 & 60 units Solution for injection professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
